Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.

Saved in:
Bibliographic Details
Title: Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Authors: Raoof S; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Mulford IJ; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Frisco-Cabanos H; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Nangia V; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Timonina D; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Labrot E; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Hafeez N; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Bilton SJ; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Drier Y; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Ji F; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Greenberg M; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Williams A; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Kattermann K; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Damon L; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA., Sovath S; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Rakiec DP; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Korn JM; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Ruddy DA; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Benes CH; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Hammerman PS; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Piotrowska Z; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Sequist LV; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Niederst MJ; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Barretina J; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Engelman JA; Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Hata AN; Massachusetts General Hospital (MGH) Cancer Center, Charlestown, MA, USA. ahata@mgh.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. ahata@mgh.harvard.edu.
Source: Oncogene [Oncogene] 2019 Sep; Vol. 38 (37), pp. 6399-6413. Date of Electronic Publication: 2019 Jul 19.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5594
DOI:10.1038/s41388-019-0887-2